Vermont § 4092 - Prescription drug coverage

§ 4092. Prescription drug coverage

• (a) A health insurance plan shall not include an annual dollar limit on prescription drug
  benefits. (b) A health insurance plan shall limit a covered individual’s out-of-pocket expenditures
  for all prescription drugs to not more for self-only and family coverage per year
  than the minimum dollar amounts in effect under Section 223(c)(2)(A)(i) of the Internal Revenue Code of 1986 for self-only and family coverage, respectively. (c)(1) For prescription drug benefits offered in conjunction with a high-deductible health
  plan (HDHP), the plan shall not provide prescription drug benefits until the expenditures
  applicable to the deductible under the HDHP have met the amount of the minimum annual
  deductibles in effect for self-only and family coverage under Section 223(c)(2)(A)(i) of the Internal Revenue Code of 1986 for self-only and family coverage, respectively, except that a plan may offer first-dollar
  prescription drug benefits to the extent permitted under federal law. (2) Once the applicable expenditure amount set forth in subdivision (1) of this subsection
  has been met under the HDHP, coverage for prescription drug benefits shall begin,
  and the limit on out-of-pocket expenditures for prescription drug benefits shall be
  as specified in subsection (b) of this section. (d)(1) A health insurance plan that uses step-therapy protocols shall: (A) not require failure, including discontinuation due to lack of efficacy or effectiveness,
  diminished effect, or an adverse event, on the same drug on more than one occasion
  for covered individuals who are continuously enrolled in a plan offered by the health
  insurer or its pharmacy benefit manager; and (B) grant an exception to its step-therapy protocols upon request of a covered individual
  or the covered individual’s treating health care professional under the same time
  parameters as set forth for prior authorization requests in 18 V.S.A. § 9418b(g)(4) if any one or more of the following conditions apply: (i) the prescription drug required under the step-therapy protocol is contraindicated
  or will likely cause an adverse reaction or physical or mental harm to the covered
  individual; (ii) the prescription drug required under the step-therapy protocol is expected to be ineffective
  based on the covered individual’s known clinical history, condition, and prescription
  drug regimen; (iii) the covered individual has already tried the prescription drugs on the protocol, or
  other prescription drugs in the same pharmacologic class or with the same mechanism
  of action, which have been discontinued due to lack of efficacy or effectiveness,
  diminished effect, or an adverse event, regardless of whether the covered individual
  was covered at the time on a plan offered by the current insurer or its pharmacy benefit
  manager; (iv) the covered individual is stable on a prescription drug selected by the covered individual’s
  treating health care professional for the medical condition under consideration; or (v) the step-therapy protocol or a prescription drug required under the protocol is not
  in the covered individual’s best interests because it will: (I) pose a barrier to adherence; (II) likely worsen a comorbid condition; or (III) likely decrease the covered individual’s ability to achieve or maintain reasonable
  functional ability. (2) Nothing in this subsection shall be construed to prohibit the use of tiered co-payments
  for covered individuals not subject to a step-therapy protocol. (3) Notwithstanding any provision of subdivision (1) of this subsection to the contrary,
  a health insurance shall not utilize a step-therapy, “fail first,” or other protocol
  that requires documented trials of a prescription drug, including a trial documented
  through a “MedWatch” (FDA Form 3500), before approving a prescription for the treatment
  of substance use disorder. (e)(1) A health insurance plan shall not require, as a condition of coverage, use of drugs
  not indicated by the U.S. Food and Drug Administration for the condition diagnosed
  and being treated under the supervision of a health care professional. (2) Nothing in this subsection shall be construed to prevent a health care professional
  from prescribing a prescription drug for off-label use. (f) A health insurance plan shall apply the same cost-sharing requirements to interchangeable
  biological products as apply to generic drugs under the plan. (g)(1) A health insurance plan shall limit a covered individual’s total out-of-pocket responsibility
  for prescription insulin drugs to not more than $100.00 per 30-day supply, regardless
  of the amount, type, or number of insulin drugs prescribed for the covered individual. (2) The $100.00 monthly limit on out-of-pocket spending for prescription insulin drugs
  set forth in subdivision (1) of this subsection shall apply regardless of whether
  the covered individual has satisfied any applicable deductible requirement under the
  health insurance plan. (h) A health insurance plan shall cover, without requiring prior authorization, at least
  one readily available asthma controller drug from each class of drug and mode of administration.
  As used in this subsection, “readily available” means that the medication is not listed
  on a national drug shortage list, including lists maintained by the U.S. Food and
  Drug Administration and by the American Society of Health-System Pharmacists. (i) On a periodic basis but not less than once per calendar year, each health insurer
  shall notify all individuals covered under its health insurance plans of any changes
  in pharmaceutical coverage and provide access to the preferred drug list maintained
  by the health insurer or its pharmacy benefit manager. (j) The Department of Financial Regulation shall enforce this section and may adopt rules
  as necessary to carry out the purposes of this section. (k) A health insurance plan shall provide coverage for prescription drugs purchased in
  Canada and used in Canada or reimported legally on the same benefit terms and conditions
  as prescription drugs purchased in this country. For drugs purchased by mail or through
  the internet, the plan may require accreditation by the Internet and Mailorder Pharmacy
  Accreditation Commission (IMPAC™) or similar organization. (Recodified and amended 2025, No. 11, § 2, eff. September 1, 2025.)